The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
International medical case reports journal – January 01, 2023
Source: PubMed
Summary
A patient suffering from treatment-resistant neuropsychiatric Lyme disease found remarkable relief through carefully measured microdoses of psilocybin. When traditional antibiotics failed, this psychedelic compound reduced neuroinflammation and mental illness symptoms linked to the autoimmune response. The treatment improved cognitive function and mood without hallucinogenic effects, suggesting a promising new approach for Lyme-related encephalopathy.
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms remitted when he began psilocybin in microdosed (sub-hallucinogenic) amounts. A literature review of its therapeutic benefits reveals that psilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation. The role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.